New approaches to structure-based discovery of dengue protease inhibitors.

@article{Tomlinson2009NewAT,
  title={New approaches to structure-based discovery of dengue protease inhibitors.},
  author={Suzanne M. Tomlinson and Robert D. Malmstrom and Stanley J. Watowich},
  journal={Infectious disorders drug targets},
  year={2009},
  volume={9 3},
  pages={
          327-43
        }
}
Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical… 

Tables from this paper

Ten years of dengue drug discovery: progress and prospects.

Peptides as Therapeutic Agents for Dengue Virus

The design of peptide drugs, antiviral activities and mechanisms of peptides and peptidomimetics (modified peptides) action against dengue virus are discussed, with a focus on the three main targets, namely, the host cell receptors, viral structural proteins and viral non-structural proteins.

Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.

Mechanistic approach of drug discovery from natural substances for thrombocytopenia: A major cause of death in dengue fever patients

High mobility group box 1 (HMGB1), emerging molecular mechanism underlying the regulation of pathogen-associated molecular patterns (PAMPs)-induced HMGB1 secretion, helpful in future for developing strategies to come with new drugs.

New developments in flavivirus drug discovery

  • W. M. Kok
  • Biology
    Expert opinion on drug discovery
  • 2016
This review describes some of the recent discoveries in the field of flavivirus inhibitor development, with a particular focus on targeting viral proteins, and focuses on the advances published during the 2012–2015 period.

Molecular herbal inhibitors of Dengue virus: an update

With the advent of synthetic biology and metagenomics and high throughput screening, it have become possible to screen and produce plant based effector molecules into microorganism like E. coli at larger amount and at relatively low cost.

Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds

Evaluating the pharmacophoric characteristics of promising compounds against NS2B/NS3pro reported in the past 10 years found several groups were associated with biological activity against dengue, including nitro, catechol, halogen and ammonium quaternaries, which seem to be potential pharmacophores that can be further investigated to treat d Dengue infections.

Natural Products as Source of Potential Dengue Antivirals

In this review, an assortment of natural products that have been reported as possessing dengue antiviral activity are described and organized into classes of substances.
...

References

SHOWING 1-3 OF 3 REFERENCES

Flaviviridae :T he Viruses and Their Replication

The present research attacked the Flavivirus infection through two mechanisms: Membrane Reorganization and the Compartmentalization and Assembly and Release of Particles from Flaviv virus-infected Cells and Host Resistance to Flaviviral Infection.

Flaviviridae: The Viruses and Their Replication, in Fundamental Virology, 4th Ed

  • 2001

Discovering Dengue DrugsFig

  • www.worldcommunitygrid.org)
  • 2008